614:
158:
558:
530:
813:. Clearly this is a pretty mature article so the impact of PBB edits is proportionally less. (And this was also one of our first edits, and in retrospect, I would not have added the summary and further reading sections where reasonable summaries and reference lists exist.) Was there a particular reason you also wanted to disable the infobox updates? Not trying to convince you otherwise, just trying to understand for the purposes of making sure PBB plays nicely with human editors...
142:
351:
330:
638:
299:
674:
1090:
440:
419:
450:
213:
882:
osteoclast activating factor has a bunch of different names that it goes by and I think it has sorta evolved with time. I am impressed by the first sentence / alternate names of TNF-alpha and wish someone would do the same for
Osteoclast activating factor. Off the top of my head I think it is IL-6
969:
Why does the first sentence include the line "formerly known as tumor necrosis factor-alpha or TNF-α" when it is still currently known as TNF-α? I see that there is a section at the bottom citing a paper which declares the opinion that it should be simply called 'TNF', but this should not imply that
1006:
That's just wrong. "tumor necrosis factor-α" is still being used. E.g. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014 Jun 18;311(23):2406-13. doi: 10.1001/jama.2014.5613. I'm going to change it.
775:
I removed the offending phrase (as I am about to refer people to the page). Out of curiosity, I just went back and checked the history. It was clearly an editing glitch, with the phrase left over from what is now covered in the second sentence. -- Bob Kerns
827:
I'm currently studying this stuff, so I'm no expert, but I'm noticing some confusion. Wouldn't it make sense to merge the entry on TNF with the present one? It could start with a general discussion of TNF and then differentiate between the two types.
623:
540:
135:
915:
150:
760:, which in turn causes many of the clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, and psoriasis. These disorders are sometimes
604:
797:
How about Tumor
Necrosis Factor beta? It is not discussed at all in this page. TNF-alpha is involved in Toxic Shock Syndrome among other things. I can't find any decent (recent) reviews on the topic.
1045:
This article uses TNFα without a hyphen. Elsewhere on wikipedia (such as when discussing TNF-ß), and in some literature, we see it with. Which usage is standard, or can both forms be freely used? --
1288:
254:
646:
544:
905:
1273:
598:
856:
I disagree with the proposed merger because there are (as of 2007) 19 identified members of the TNF family. I agree that this main page is much better than the TNF family ("factor
468:
171:
1095:
472:
223:
916:
http://www.google.com/search?hl=en&safe=off&client=firefox-a&rls=org.mozilla%3Aen-US%3Aofficial&hs=9EO&q=osteoclast+activating+factor+IL-1&btnG=Search
1128:
771:
I noticed the above contradiction as well and think the first part of the phrase must be an error. However, I'm not a medical expert, so I don't dare edit the TNF page.
1293:
1060:
I see many 2020 journal articles referring to TNF-α, so I see no basis for the claim that this name is obsolete. I have modified this reference in the introduction. --
401:
248:
1118:
574:
1243:
391:
44:
735:
79:
184:
512:
1268:
1248:
1100:
565:
535:
367:
842:
I agree. It is clear to me that this article is much better than the ] article (which contains very little). I strongly suggest that they are merged.
1258:
906:
http://www.google.com/search?q=osteoclast+activating+factor&ie=utf-8&oe=utf-8&aq=t&rls=org.mozilla:en-US:official&client=firefox-a
502:
1303:
85:
1263:
1238:
984:
I totally agree. I the term "TNF" is completely ambiguous, if you read the literature (i.e. pubmed) everyone refers to the cytokine as TNF-α.
767:
This seems contradictory. If inhibition of TNFa promotes the inflammatory response, why would you treat these conditions by inhibiting TNFa??
651:
477:
1167:
685:
358:
335:
267:
1283:
991:
950:
706:. Further reviews are welcome from any editor who has not contributed significantly to this article (or nominated it), and can be added to
628:
30:
924:
890:
829:
1253:
1189:
1123:
703:
99:
463:
424:
104:
20:
613:
74:
310:
1298:
1146:
708:
65:
1278:
860:") page, but the family page needs updating and expansion. The expansion would make it unwieldy inside the main TNF page.
191:
847:
753:--- why is it called 'tumor necrosis factor' -- some background would be good, I'll see what I can find --hmackiernan
282:
876:
713:
109:
1219:
1161:
695:
1142:
1028:
126:
995:
954:
316:
833:
198:
1050:
928:
894:
843:
987:
946:
920:
886:
1204:
1183:
1031:
which affects this page. Please participate on that page and not in this talk page section. Thank you. —
55:
573:
on
Knowledge (XXG). If you would like to participate, please visit the project page, where you can join
366:
on
Knowledge (XXG). If you would like to participate, please visit the project page, where you can join
24:
70:
1215:
1157:
691:
262:
177:
298:
785:
1046:
975:
810:
743:
861:
1201:
1179:
1065:
1012:
570:
51:
910:
557:
529:
455:
165:
865:
814:
228:
1232:
1032:
971:
806:
739:
350:
329:
1061:
1008:
702:
An editor has indicated a willingness to review the article in accordance with the
637:
363:
1223:
1208:
1193:
1171:
1068:
1054:
1035:
1016:
999:
979:
958:
932:
898:
869:
851:
837:
817:
788:
748:
445:
1149:. The edit link for this section can be used to add comments to the review.
1214:
Do you still plan on reviewing this? Following up since it's been 7 days.
125:
276:
243:
439:
418:
212:
883:
and a subtype of IL-1. But I'm probably wrong so please verify.
221:
for
Knowledge (XXG)'s health content are defined in the guideline
475:. Please visit the project page for details or ask questions at
141:
823:
More general entry: TNF, then subheadings TNF-alpha, TNF-beta?
668:
292:
207:
15:
809:, just wondering why you chose to disable all updates of the
467:, which recommends that medicine-related articles follow the
636:
612:
712:, but the decision whether or not to list the article as a
943:
Why did you remove the clooned form in the consept.....
911:
http://www.grt.kyushu-u.ac.jp/spad/account/ligand/il1.html
875:
the first sentence is very good. can you do the same for
149:
784:
doesnt tnf block instead of cause viral replication???
224:
Knowledge (XXG):Identifying reliable sources (medicine)
758:
Inhibition of TNFα promotes the inflammatory response
569:, a collaborative effort to improve the coverage of
362:, a collaborative effort to improve the coverage of
1289:
WikiProject
Molecular and Cellular Biology articles
649:, a task force which is currently considered to be
268:
clinical publications about evidence-based medicine
197:
603:This article has not yet received a rating on the
33:for general discussion of the article's subject.
471:and that biomedical information in any article
1274:Unknown-importance Molecular Biology articles
583:Knowledge (XXG):WikiProject Molecular Biology
469:Manual of Style for medicine-related articles
157:
8:
1078:
1027:There is a move discussion in progress on
524:
413:
324:
970:everyone else is following this opinion.
624:the Molecular and Cell Biology task force
478:Knowledge (XXG) talk:WikiProject Medicine
376:Knowledge (XXG):WikiProject Pharmacology
249:review articles from the past five years
1294:All WikiProject Molecular Biology pages
1109:
1081:
526:
415:
326:
296:
586:Template:WikiProject Molecular Biology
1199:From the GARC, going to review this.
716:should be left to the first reviewer.
183:
7:
1244:Mid-importance pharmacology articles
734:I found some historical information
684:is currently a Biology and medicine
645:This article is within the scope of
563:This article is within the scope of
487:Knowledge (XXG):WikiProject Medicine
461:This article is within the scope of
356:This article is within the scope of
277:Centre for Reviews and Dissemination
315:It is of interest to the following
23:for discussing improvements to the
1269:B-Class Molecular Biology articles
698:) at 02:00, 1 September 2024 (UTC)
14:
1249:WikiProject Pharmacology articles
379:Template:WikiProject Pharmacology
274:Other potential sources include:
50:New to Knowledge (XXG)? Welcome!
1259:Mid-importance medicine articles
672:
556:
528:
473:use high-quality medical sources
448:
438:
417:
349:
328:
297:
211:
45:Click here to start a new topic.
1304:Good article nominees on review
507:This article has been rated as
396:This article has been rated as
1264:All WikiProject Medicine pages
1224:00:39, 13 September 2024 (UTC)
1147:Talk:Tumor necrosis factor/GA1
965:the cytokine formerly known as
959:22:56, 14 September 2009 (UTC)
1:
1239:B-Class pharmacology articles
1209:01:20, 5 September 2024 (UTC)
1194:01:20, 5 September 2024 (UTC)
1172:02:00, 1 September 2024 (UTC)
1069:15:03, 30 December 2020 (UTC)
1017:05:31, 26 December 2014 (UTC)
980:15:52, 15 February 2013 (UTC)
818:18:01, 13 November 2007 (UTC)
749:12:00, 11 December 2005 (UTC)
647:the Cell Signaling task force
621:This article is supported by
577:and see a list of open tasks.
566:WikiProject Molecular Biology
490:Template:WikiProject Medicine
370:and see a list of open tasks.
235:sources of information about
42:Put new text under old text.
877:osteoclast activating factor
789:14:52, 19 January 2007 (UTC)
1284:Mid-importance MCB articles
1023:Move discussion in progress
838:13:30, 6 January 2008 (UTC)
1320:
933:07:56, 28 April 2008 (UTC)
899:07:53, 28 April 2008 (UTC)
762:treated by inhibiting TNFα
720:Short description: Protein
589:Molecular Biology articles
513:project's importance scale
402:project's importance scale
1254:B-Class medicine articles
1055:00:47, 28 June 2018 (UTC)
1000:16:07, 6 March 2013 (UTC)
870:06:40, 26 July 2011 (UTC)
644:
620:
602:
551:
506:
433:
395:
344:
323:
80:Be welcoming to newcomers
1036:07:59, 15 May 2013 (UTC)
1029:Talk:Interferon, alpha 1
852:15:29, 4 July 2010 (UTC)
359:WikiProject Pharmacology
802:disabling auto updates
641:
617:
305:This article is rated
75:avoid personal attacks
1299:Good article nominees
704:good article criteria
682:Tumor necrosis factor
640:
616:
382:pharmacology articles
309:on Knowledge (XXG)'s
237:Tumor necrosis factor
123:Find medical sources:
100:Neutral point of view
25:Tumor necrosis factor
1279:B-Class MCB articles
686:good article nominee
464:WikiProject Medicine
255:free review articles
231:. Here are links to
105:No original research
642:
618:
311:content assessment
227:and are typically
129:
86:dispute resolution
47:
1137:
1136:
990:comment added by
949:comment added by
935:
923:comment added by
901:
889:comment added by
844:JustAnotherKinase
780:viral replication
746:
727:
726:
721:
699:
667:
666:
663:
662:
659:
658:
580:Molecular Biology
571:Molecular Biology
536:Molecular Biology
523:
522:
519:
518:
493:medicine articles
412:
411:
408:
407:
291:
290:
206:
205:
128:Source guidelines
127:
66:Assume good faith
43:
1311:
1207:
1091:Copyvio detector
1079:
1002:
961:
918:
884:
744:
719:
689:
676:
675:
669:
605:importance scale
591:
590:
587:
584:
581:
560:
553:
552:
547:
532:
525:
495:
494:
491:
488:
485:
458:
453:
452:
451:
442:
435:
434:
429:
421:
414:
384:
383:
380:
377:
374:
353:
346:
345:
340:
332:
325:
308:
302:
301:
293:
215:
208:
202:
201:
187:
161:
153:
145:
131:
95:Article policies
16:
1319:
1318:
1314:
1313:
1312:
1310:
1309:
1308:
1229:
1228:
1216:AdeptLearner123
1200:
1158:AdeptLearner123
1141:This review is
1133:
1105:
1077:
1043:
1025:
985:
967:
962:
944:
880:
825:
804:
782:
732:
723:
709:the review page
692:AdeptLearner123
673:
588:
585:
582:
579:
578:
538:
492:
489:
486:
483:
482:
456:Medicine portal
454:
449:
447:
427:
381:
378:
375:
372:
371:
338:
306:
233:possibly useful
229:review articles
121:
116:
115:
114:
91:
61:
12:
11:
5:
1317:
1315:
1307:
1306:
1301:
1296:
1291:
1286:
1281:
1276:
1271:
1266:
1261:
1256:
1251:
1246:
1241:
1231:
1230:
1227:
1226:
1198:
1152:
1151:
1135:
1134:
1132:
1131:
1126:
1121:
1115:
1112:
1111:
1107:
1106:
1104:
1103:
1101:External links
1098:
1093:
1087:
1084:
1083:
1076:
1073:
1072:
1071:
1042:
1039:
1024:
1021:
1020:
1019:
992:152.23.176.212
966:
963:
951:85.147.153.152
942:
941:
940:
939:
938:
937:
936:
879:
873:
824:
821:
803:
800:
799:
795:
793:
781:
778:
773:
769:
731:
728:
725:
724:
679:
677:
665:
664:
661:
660:
657:
656:
643:
633:
632:
629:Mid-importance
619:
609:
608:
601:
595:
594:
592:
575:the discussion
561:
549:
548:
545:Cell Signaling
533:
521:
520:
517:
516:
509:Mid-importance
505:
499:
498:
496:
460:
459:
443:
431:
430:
428:Mid‑importance
422:
410:
409:
406:
405:
398:Mid-importance
394:
388:
387:
385:
368:the discussion
354:
342:
341:
339:Mid‑importance
333:
321:
320:
314:
303:
289:
288:
287:
286:
272:
259:
240:
216:
204:
203:
118:
117:
113:
112:
107:
102:
93:
92:
90:
89:
82:
77:
68:
62:
60:
59:
48:
39:
38:
35:
34:
28:
13:
10:
9:
6:
4:
3:
2:
1316:
1305:
1302:
1300:
1297:
1295:
1292:
1290:
1287:
1285:
1282:
1280:
1277:
1275:
1272:
1270:
1267:
1265:
1262:
1260:
1257:
1255:
1252:
1250:
1247:
1245:
1242:
1240:
1237:
1236:
1234:
1225:
1221:
1217:
1213:
1212:
1211:
1210:
1206:
1203:
1196:
1195:
1191:
1188:
1185:
1181:
1178:
1174:
1173:
1169:
1166:
1163:
1159:
1156:
1150:
1148:
1144:
1139:
1138:
1130:
1127:
1125:
1122:
1120:
1117:
1116:
1114:
1113:
1108:
1102:
1099:
1097:
1094:
1092:
1089:
1088:
1086:
1085:
1080:
1074:
1070:
1067:
1063:
1059:
1058:
1057:
1056:
1052:
1048:
1047:James Chenery
1040:
1038:
1037:
1034:
1030:
1022:
1018:
1014:
1010:
1005:
1004:
1003:
1001:
997:
993:
989:
982:
981:
977:
973:
964:
960:
956:
952:
948:
934:
930:
926:
925:75.43.212.236
922:
917:
914:
913:
912:
909:
908:
907:
904:
903:
902:
900:
896:
892:
891:75.43.212.236
888:
878:
874:
872:
871:
867:
863:
859:
854:
853:
849:
845:
840:
839:
835:
831:
830:85.178.26.162
822:
820:
819:
816:
812:
811:ProteinBoxBot
808:
801:
798:
794:
791:
790:
787:
779:
777:
772:
768:
765:
763:
759:
754:
751:
750:
747:
741:
737:
729:
722:
717:
715:
711:
710:
705:
700:
697:
693:
690:Nominated by
687:
683:
678:
671:
670:
654:
653:
648:
639:
635:
634:
630:
627:(assessed as
626:
625:
615:
611:
610:
606:
600:
597:
596:
593:
576:
572:
568:
567:
562:
559:
555:
554:
550:
546:
542:
537:
534:
531:
527:
514:
510:
504:
501:
500:
497:
480:
479:
474:
470:
466:
465:
457:
446:
444:
441:
437:
436:
432:
426:
423:
420:
416:
403:
399:
393:
390:
389:
386:
369:
365:
361:
360:
355:
352:
348:
347:
343:
337:
334:
331:
327:
322:
318:
312:
304:
300:
295:
294:
285:
284:
279:
278:
273:
270:
269:
264:
263:TRIP database
260:
257:
256:
251:
250:
245:
242:
241:
238:
234:
230:
226:
225:
220:
219:Ideal sources
217:
214:
210:
209:
200:
196:
193:
190:
186:
182:
179:
176:
173:
172:ScienceDirect
170:
167:
164:
160:
156:
152:
148:
144:
140:
137:
134:
130:
124:
120:
119:
111:
110:Verifiability
108:
106:
103:
101:
98:
97:
96:
87:
83:
81:
78:
76:
72:
69:
67:
64:
63:
57:
53:
52:Learn to edit
49:
46:
41:
40:
37:
36:
32:
26:
22:
18:
17:
1197:
1186:
1180:TheNuggeteer
1176:
1175:
1164:
1154:
1153:
1140:
1129:Instructions
1044:
1041:Nomenclature
1026:
986:— Preceding
983:
968:
881:
857:
855:
841:
826:
805:
796:
792:
783:
774:
770:
766:
761:
757:
755:
752:
733:
718:
714:good article
707:
701:
681:
680:
650:
622:
564:
508:
476:
462:
397:
373:Pharmacology
364:Pharmacology
357:
336:Pharmacology
317:WikiProjects
281:
275:
266:
253:
247:
236:
232:
222:
218:
194:
188:
180:
174:
168:
162:
154:
146:
138:
132:
122:
94:
19:This is the
1143:transcluded
945:—Preceding
919:—Preceding
885:—Preceding
31:not a forum
1233:Categories
1155:Nominator:
1096:Authorship
1082:GA toolbox
252:(limit to
1202:🍗TheNugg
1177:Reviewer:
1119:Templates
1110:Reviewing
1075:GA Review
815:AndrewGNF
265:provides
246:provides
88:if needed
71:Be polite
21:talk page
1190:contribs
1168:contribs
1124:Criteria
1062:Ben Best
1033:RMCD bot
988:unsigned
972:markwdck
947:unsigned
921:unsigned
887:unsigned
807:Arcadian
786:Martious
730:Untitled
652:inactive
484:Medicine
425:Medicine
178:Springer
143:Cochrane
56:get help
29:This is
27:article.
1205:eteer🍗
1009:Nbauman
511:on the
400:on the
307:B-class
313:scale.
244:PubMed
166:OpenMD
136:PubMed
1145:from
192:Wiley
84:Seek
1220:talk
1184:talk
1162:talk
1066:Talk
1051:talk
1013:talk
996:talk
976:talk
955:talk
929:talk
895:talk
866:talk
862:C4dn
848:talk
834:talk
745:T@lk
736:here
696:talk
280:and
261:The
185:Trip
159:Gale
151:DOAJ
73:and
740:JFW
599:???
541:MCB
503:Mid
392:Mid
283:CDC
199:TWL
1235::
1222:)
1192:)
1170:)
1053:)
1015:)
1007:--
998:)
978:)
957:)
931:)
897:)
868:)
850:)
836:)
764:"
742:|
738:.
688:.
631:).
543:/
539::
54:;
1218:(
1187:·
1182:(
1165:·
1160:(
1064::
1049:(
1011:(
994:(
974:(
953:(
927:(
893:(
864:(
858:s
846:(
832:(
756:"
694:(
655:.
607:.
515:.
481:.
404:.
319::
271:.
258:)
239:.
195:·
189:·
181:·
175:·
169:·
163:·
155:·
147:·
139:·
133:·
58:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
